Assessment of corneal sensation, innervation and retinal nerve fiber layer in patients treated with multiple intravitreal ranibizumab injections

Gulfidan Bitirgen, Selman Belviranli, Rayaz Malik, Hurkan Kerimoglu, Gunhal Satirtav, Nazmi Zengin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: To evaluate the effects of repeated intravitreal ranibizumab injections on corneal sensitivity, corneal sub-basal nerve plexus (SBNP) and peripapillary retinal nerve fiber layer (RNFL) thickness in patients with neovascular age-related macular degeneration (AMD). Methods: Sixty-six eyes of 33 patients who had received unilateral repeated intravitreal ranibizumab injections (0.5 mg/0.05 ml) for the treatment of AMD and 25 eyes of 25 healthy subjects were included in the study. Central corneal sensation was measured using the contact Cochet-Bonnet esthesiometer. The laser scanning in vivo corneal confocal microscope was used to determine corneal SBNP parameters. The peripapillary RNFL thickness was assessed with spectral-domain optical coherence tomography. Data obtained from the ranibizumab-injected eyes were compared with those of the fellow non-treated eyes and the eyes of the healthy control subjects. Results: The mean number of ranibizumab injections per eye was 8.9±5.0 (range 3-20). There were no statistically significant differences in the central corneal sensitivity threshold and corneal SBNP parameters between the ranibizumab-injected eyes and the fellow untreated eyes or between those with neovascular AMD and the healthy control group (P>0.05 for all). The average peripapillary RNFL thickness of the treated eyes did not differ significantly to the fellow eyes (P = 0.237), and the eyes of healthy control subjects (P = 0.918). There were no significant correlations between the number of ranibizumab injections and any of the study parameters. Conclusions: Multiple intravitreal injections of ranibizumab seem to have no harmful effects on corneal sensitivity, innervation and peripapillary RNFL thickness in patients with AMD.

Original languageEnglish
Article numbere0170271
JournalPLoS One
Volume12
Issue number1
DOIs
Publication statusPublished - 1 Jan 2017

Fingerprint

Intravitreal Injections
nerve fibers
innervation
Nerve Fibers
eyes
Fibers
Macular Degeneration
plexus
Healthy Volunteers
nerve tissue
Optical tomography
intravitreal injection
Ranibizumab
injection
Microscopes
Injections
tomography
Optical Coherence Tomography
Scanning
microscopes

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Assessment of corneal sensation, innervation and retinal nerve fiber layer in patients treated with multiple intravitreal ranibizumab injections. / Bitirgen, Gulfidan; Belviranli, Selman; Malik, Rayaz; Kerimoglu, Hurkan; Satirtav, Gunhal; Zengin, Nazmi.

In: PLoS One, Vol. 12, No. 1, e0170271, 01.01.2017.

Research output: Contribution to journalArticle

Bitirgen, Gulfidan ; Belviranli, Selman ; Malik, Rayaz ; Kerimoglu, Hurkan ; Satirtav, Gunhal ; Zengin, Nazmi. / Assessment of corneal sensation, innervation and retinal nerve fiber layer in patients treated with multiple intravitreal ranibizumab injections. In: PLoS One. 2017 ; Vol. 12, No. 1.
@article{f9d74a1b06e442cc993e45ff50af470a,
title = "Assessment of corneal sensation, innervation and retinal nerve fiber layer in patients treated with multiple intravitreal ranibizumab injections",
abstract = "Purpose: To evaluate the effects of repeated intravitreal ranibizumab injections on corneal sensitivity, corneal sub-basal nerve plexus (SBNP) and peripapillary retinal nerve fiber layer (RNFL) thickness in patients with neovascular age-related macular degeneration (AMD). Methods: Sixty-six eyes of 33 patients who had received unilateral repeated intravitreal ranibizumab injections (0.5 mg/0.05 ml) for the treatment of AMD and 25 eyes of 25 healthy subjects were included in the study. Central corneal sensation was measured using the contact Cochet-Bonnet esthesiometer. The laser scanning in vivo corneal confocal microscope was used to determine corneal SBNP parameters. The peripapillary RNFL thickness was assessed with spectral-domain optical coherence tomography. Data obtained from the ranibizumab-injected eyes were compared with those of the fellow non-treated eyes and the eyes of the healthy control subjects. Results: The mean number of ranibizumab injections per eye was 8.9±5.0 (range 3-20). There were no statistically significant differences in the central corneal sensitivity threshold and corneal SBNP parameters between the ranibizumab-injected eyes and the fellow untreated eyes or between those with neovascular AMD and the healthy control group (P>0.05 for all). The average peripapillary RNFL thickness of the treated eyes did not differ significantly to the fellow eyes (P = 0.237), and the eyes of healthy control subjects (P = 0.918). There were no significant correlations between the number of ranibizumab injections and any of the study parameters. Conclusions: Multiple intravitreal injections of ranibizumab seem to have no harmful effects on corneal sensitivity, innervation and peripapillary RNFL thickness in patients with AMD.",
author = "Gulfidan Bitirgen and Selman Belviranli and Rayaz Malik and Hurkan Kerimoglu and Gunhal Satirtav and Nazmi Zengin",
year = "2017",
month = "1",
day = "1",
doi = "10.1371/journal.pone.0170271",
language = "English",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - Assessment of corneal sensation, innervation and retinal nerve fiber layer in patients treated with multiple intravitreal ranibizumab injections

AU - Bitirgen, Gulfidan

AU - Belviranli, Selman

AU - Malik, Rayaz

AU - Kerimoglu, Hurkan

AU - Satirtav, Gunhal

AU - Zengin, Nazmi

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Purpose: To evaluate the effects of repeated intravitreal ranibizumab injections on corneal sensitivity, corneal sub-basal nerve plexus (SBNP) and peripapillary retinal nerve fiber layer (RNFL) thickness in patients with neovascular age-related macular degeneration (AMD). Methods: Sixty-six eyes of 33 patients who had received unilateral repeated intravitreal ranibizumab injections (0.5 mg/0.05 ml) for the treatment of AMD and 25 eyes of 25 healthy subjects were included in the study. Central corneal sensation was measured using the contact Cochet-Bonnet esthesiometer. The laser scanning in vivo corneal confocal microscope was used to determine corneal SBNP parameters. The peripapillary RNFL thickness was assessed with spectral-domain optical coherence tomography. Data obtained from the ranibizumab-injected eyes were compared with those of the fellow non-treated eyes and the eyes of the healthy control subjects. Results: The mean number of ranibizumab injections per eye was 8.9±5.0 (range 3-20). There were no statistically significant differences in the central corneal sensitivity threshold and corneal SBNP parameters between the ranibizumab-injected eyes and the fellow untreated eyes or between those with neovascular AMD and the healthy control group (P>0.05 for all). The average peripapillary RNFL thickness of the treated eyes did not differ significantly to the fellow eyes (P = 0.237), and the eyes of healthy control subjects (P = 0.918). There were no significant correlations between the number of ranibizumab injections and any of the study parameters. Conclusions: Multiple intravitreal injections of ranibizumab seem to have no harmful effects on corneal sensitivity, innervation and peripapillary RNFL thickness in patients with AMD.

AB - Purpose: To evaluate the effects of repeated intravitreal ranibizumab injections on corneal sensitivity, corneal sub-basal nerve plexus (SBNP) and peripapillary retinal nerve fiber layer (RNFL) thickness in patients with neovascular age-related macular degeneration (AMD). Methods: Sixty-six eyes of 33 patients who had received unilateral repeated intravitreal ranibizumab injections (0.5 mg/0.05 ml) for the treatment of AMD and 25 eyes of 25 healthy subjects were included in the study. Central corneal sensation was measured using the contact Cochet-Bonnet esthesiometer. The laser scanning in vivo corneal confocal microscope was used to determine corneal SBNP parameters. The peripapillary RNFL thickness was assessed with spectral-domain optical coherence tomography. Data obtained from the ranibizumab-injected eyes were compared with those of the fellow non-treated eyes and the eyes of the healthy control subjects. Results: The mean number of ranibizumab injections per eye was 8.9±5.0 (range 3-20). There were no statistically significant differences in the central corneal sensitivity threshold and corneal SBNP parameters between the ranibizumab-injected eyes and the fellow untreated eyes or between those with neovascular AMD and the healthy control group (P>0.05 for all). The average peripapillary RNFL thickness of the treated eyes did not differ significantly to the fellow eyes (P = 0.237), and the eyes of healthy control subjects (P = 0.918). There were no significant correlations between the number of ranibizumab injections and any of the study parameters. Conclusions: Multiple intravitreal injections of ranibizumab seem to have no harmful effects on corneal sensitivity, innervation and peripapillary RNFL thickness in patients with AMD.

UR - http://www.scopus.com/inward/record.url?scp=85009275209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009275209&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0170271

DO - 10.1371/journal.pone.0170271

M3 - Article

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e0170271

ER -